Averting the SaaS Apocalypse with Simon Taylor
Listen now
Description
It's not a matter of if, it's a matter of when. If you've never been the victim of a cyberattack or a data breach, the chances are that you will be soon. Ranging from simple phishing emails to elaborate and highly-coordinated campaigns to steal government secrets, the severity of cyberattacks all across the globe is intensifying. And the need to for best-in-class security vendors -- to proactively protect you before an "oh shoot" moment occurs -- has never been greater. Yet how do we know who to trust? There are also thousands of cybersecurity providers who offer services to protect against cybercrime. That ranges from small startups with a clever idea, to independent corporations like CrowdStrike (Nasdaq: CRWD) or SentinelOne (NYSE: S) who leaders in their niche, to consolidated behemoths like Microsoft  (Nasdaq: MSFT) and Palo Alto Networks (Nasdaq: PANW) with a full suite of products. There's an massive pool of vendors to choose from. According to research from Cisco (Nasdaq: CSC), 13% of companies are working with at least 20 different vendors for cybersecurity alone. So how should companies differentiate themselves in this crowded field? What dangerous security vulnerabilities still aren't yet adequately protected against? And how should investors figure out which publicly-traded companies to put their money behind? To help us answer those questions, we’ve brought in an expert. 7investing CEO Simon Erickson recently spoke with Simon Taylor, who is the founder and CEO of HYCU, about how to tune out the noise and look for the true winners in this space. --- Send in a voice message: https://podcasters.spotify.com/pod/show/7investing/message
More Episodes
If you’ve ever travelled abroad or tried to send money across international borders, hidden fees and unfair exchange rates have no doubt been a massive and expensive headache. In this week’s episode of the 7investing podcast, Lead Advisors Luke Hallard & Krzysztof Piekarski sit down with...
Published 04/16/24
Published 04/16/24
ShockWave Medical (Nasdaq: SWAV), the innovative pioneer of intravascular lithotripsy, has received an all-cash acquisition offer from Johnson & Johnson (NYSE: JNJ) for $335 per share. In today's episode, 7investing advisors Luke Hallard and Simon Erickson discuss why we made ShockWave a...
Published 04/05/24